Cline Christopher R. 4

4 · Travere Therapeutics, Inc. · Filed Feb 3, 2026

AI-generated summary of this filing

Updated Feb 4, 2026

Travere (TVTX) CFO Christopher Cline Sells 7,242 Shares

What Happened

Christopher R. Cline, Chief Financial Officer of Travere Therapeutics (TVTX), had two grant transactions on Jan 31, 2026 and a sale on Feb 3, 2026. He was granted 28,130 restricted stock units (RSUs) and 75,000 additional equity units (derivative award). On Feb 3 he sold 7,242 shares in an open-market transaction at $32.12 per share, generating proceeds of $232,613.
The 28,130 awards are RSUs (each converts to one share upon settlement). The 75,000 derivative award is subject to a vesting schedule. The sale appears to be a routine sell-to-cover to satisfy tax withholding related to the RSU settlement (see Key Details).

Key Details

Transaction dates and prices:
- Jan 31, 2026: Grant — 28,130 RSUs @ $0.00 (F1).
- Jan 31, 2026: Grant — 75,000 derivative units @ $0.00 (vesting applies) (F3).
- Feb 3, 2026: Sale — 7,242 shares @ $32.12 = $232,613 (F2).
Shares owned after the transaction: Not disclosed in the provided filing excerpt.
Notable footnotes from the filing:
- F1: Each RSU represents a contingent right to receive one share of common stock upon settlement.
- F2: The 7,242-share sale was to cover required tax withholding at RSU settlement (a broker-directed "sell to cover"), not a discretionary trade by the reporting person.
- F3: The 75,000 derivative award follows a standard vesting schedule (one-fourth vests after one year, remainder vests in 36 equal monthly installments).
Filing timeliness: Report filed Feb 3, 2026 for transactions with a period ending Jan 31, 2026 — appears to be timely.

Context

The sale was a sell-to-cover for tax withholding tied to RSU settlement, which is common and does not necessarily signal a change in the insider’s view of the company. The grants increase potential future share exposure but are subject to vesting; they do not immediately increase tradable holdings until settled/vested.
For retail investors, purchases are typically more informative than routine grant settlements or mandated sell-to-cover transactions; this filing mainly documents compensation-related awards and the associated tax withholding sale.

Form 4

Period: 2026-01-31

CHIEF FINANCIAL OFFICER

Transactions

Award
Common Stock
[F1]
2026-01-31+28,130→ 120,213 total
Sale
Common Stock
[F2]
2026-02-03$32.12/sh−7,242$232,613→ 112,971 total
Award
Employee stock option (right to buy)
[F3]
2026-01-31+75,000→ 75,000 total
Exercise: $33.09Exp: 2036-01-31→ Common Stock (75,000 underlying)

Footnotes (3)

[F1]Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
[F2]Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
[F3]One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

Signature

/s/ Elizabeth E. Reed, Attorney-in-Fact|2026-02-03

1 file